China's Aildenafil(枸橼酸爱地那非片):Pictures,Uses,Dosage,Side Effects,Warnings-SEAGULL HEALTH

Introduction of Aildenafil

Aildenafil Citrate Tablets was first launched in China in December 2021. As the world's first PDE5 inhibitor developed based on the physiological characteristics of Chinese males, it has obtained compound patents in 22 countries and regions including China, the United States and the European Union.

Indications

For the treatment of erectile dysfunction in adult males.

Overview

Generic Name

Aildenafil Citrate Tablets,枸橼酸爱地那非片

Brand Name

爱力士

Drug Type

Rx Drug

Approval No.

30mg:国药准字H20210051;60mg:国药准字H20237153

Active Ingredient

Aildenafil

Dosage Form

30mg*2tablets;60mg*2tablets

Specification

Tablets

Description

Aildenafil is a film-coated tablet. When the coating is removed, the tablet core appears white or almost white.

Expiry Date

36 months

Manufacturer

Youcare Pharmaceutical Group Co., Ltd.

Storage

Store in a sealed container, protected from light, in a dry place, and at a temperature not exceeding 25℃.

Dosage and Administration

For oral administration. The recommended dose is 60 mg per time, to be taken approximately 1 hour before sexual activity. The maximum frequency of administration is once every 24 hours. In clinical trials, the duration of treatment with this product did not exceed 12 weeks. Note: At the recommended dose, aildenafil is ineffective without sexual stimulation.

Contraindications

Contraindicated in patients with hypersensitivity to any component of Aildenafil Citrate Tablets.

Combination contraindication with nitrates: Aildenafil can potentiate the hypotensive effect of nitrates. Therefore, it is contraindicated in patients who are taking nitric oxide donors (such as any form of organic nitrates or organic nitrites), whether on a regular or intermittent basis.

Combination contraindication with guanylate cyclase stimulators: Concomitant use of phosphodiesterase type 5 (PDE5) inhibitors, including Aildenafil, with guanylate cyclase stimulators (e.g., riociguat) is prohibited, as this may lead to symptomatic hypotension.

Adverse Reactions

After administration of this product, common adverse reactions (incidence rate ≥ 1%) include: flushing, dizziness, headache, upper abdominal discomfort, eye distension, increased alanine aminotransferase, palpitations, nasal congestion.

Rare adverse reactions (incidence rate < 1%) include: dry mouth, generalized fever, vertigo, nausea, diarrhea, hiccups, chest discomfort, chest tightness, visual abnormalities, abnormal lacrimation, tinnitus, left shoulder discomfort, increased aspartate aminotransferase, etc.

Use in Special Populations

Pregnancy and Lactation

This product is not indicated for females.

Pediatric Use

This product is not indicated for pediatric patients.

Geriatric Use

No relevant clinical trials have been conducted, and there are no reliable references available.

For more detailed drug information, please consult the official package leaflet.

Contact Information

If any issues arise, please contact us immediately.

Email:haiousales@gmail.com